Predilection of Clinical Response to Chemotherapy in Head and Neck Cancer -Correlation of Apoptosis related genes and Chemosensitivity-

头颈癌化疗临床反应的倾向-凋亡相关基因与化疗敏感性的相关性-

基本信息

  • 批准号:
    07671895
  • 负责人:
  • 金额:
    $ 0.45万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    1995
  • 资助国家:
    日本
  • 起止时间:
    1995 至 1996
  • 项目状态:
    已结题

项目摘要

1. A study of an anticancer drug sensitivity test suing the SDI test : The succinate dehydrogenase inhibition (SDI) test was carried out for 55 head and neck cancers. As a results, the evaluable rate of the SDI test was 80%. Cancer cells from the involved lumph nodes showed a tendency to low calculated inhibition rate (i. R.) as compared with those from primary tumors. The in vitro results were compared with the clinical responses of the recurrent patients who were treated by CDDP/5FU.Predictive accuracies of CDDP and 5FU were 56%and 63%, respectively.2. A study of an anticancer drug sensitivity test using the HSRA test : Histoculture drug response assay (HDRA) with MTT-endpoint was performed for 40 head and neck cancers. using a concentration-I.R.curve and a concentration-efficacy rate curve, the optimal cutoff concentration was estimated as 20mug/ml for CDDP,300mug/ml for 5FU and15mug/ for adriamycin. I.R.at CDDP 20mug/ml from the involved lumph nodes showed a significantly lower value than that of primary tumors of squamous cell carcinoma. The in vitro results at CDDP 20mug/ml were compared with the clinical responses of 13 patients who were treated by VDDP/5FU.Significant correlation between in vitro and in vivo results was observed. The predictive accuracy for response to chamotherapy was 77%.3. Immunohistochamical study : The correlation betwen an anticancer sensitibity test and the status of p53, bcl-2, Glutathione S-Transferase pi and Metallothionein (MT) using immunohistochemical staining was examined. Positive staining of p53 and MT significantly correlated with lower I.R.at CDDP 20mug/ml of HDRA assay. Their predictive accuracy for response to chemotherapy was 75% and 50%, respectively.4. Results : HDRA assay and the status of p53 using immonuhistochamical staining are extremely useful in the prediction of response to chamotheray for head and neck cancer.
1.应用SDI试验进行抗癌药敏试验的研究:对55例头颈部肿瘤进行了琥珀酸脱氢酶抑制(SDI)试验。结果,SDI测试的可评价率为80%。来自所涉及的淋巴结的癌细胞显示出低计算抑制率的趋势(即,R.)的情况下进行。与原发性肿瘤相比,结果:1.体外实验结果与复发患者经CDDP/5 FU治疗后的临床反应进行比较,CDDP和5 FU的预测准确率分别为56%和63%.一项使用HSRA试验的抗癌药物敏感性试验研究:对40例头颈部癌症进行了具有MTT终点的组织培养药物反应试验(HSP 70)。利用浓度-I.R.曲线和浓度-疗效率曲线,估计CDDP的最佳截止浓度为20 μ g/ml,5 FU为300 μ g/ml,阿霉素为15 μ g/ml。I.R.at CDDP 20 μ g/ml的淋巴结转移率明显低于鳞癌原发灶。将CDDP 20 μ g/ml的体外结果与13例经VDDP/5 FU治疗的患者的临床反应进行比较,发现体外结果与体内结果之间存在显著相关性。化疗反应的预测准确率为77%.免疫组织化学研究:用免疫组化方法检测p53、bcl-2、谷胱甘肽S转移酶(Glucose-S-Transferase,GST)π和金属硫蛋白(Metallothionein,MT)的表达与肿瘤敏感性的关系。p53和MT的阳性染色与较低的CDDP 20 μ g/ml的HSP 70测定显著相关。I.R.at它们对化疗反应的预测准确率分别为75%和50%。结果如下:应用免疫组化法检测肿瘤组织中p53蛋白的表达及抑制作用,可用于头颈部肿瘤化疗疗效的预测。

项目成果

期刊论文数量(5)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
深野 英夫: "SDI法(Succinate dehydrogenase inhibition test)を用いた抗癌剤感受性試験の臨床応用" 頭頚部腫瘍. 22. 482-487 (1996)
Hideo Fukano:“使用SDI法(琥珀酸脱氢酶抑制试验)进行抗癌药物敏感性试验的临床应用”头颈肿瘤22. 482-487(1996)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
深野英夫: "SDI法(Succinate dehydrogenase inhibition test)を用いた抗癌剤感受性試験の臨床的応用" 頭頸部腫瘍. 22. 482-487 (1996)
Hideo Fukano:“使用SDI法(琥珀酸脱氢酶抑制试验)进行抗癌药物敏感性试验的临床应用”头颈肿瘤22. 482-487(1996)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
T.OGAWA: "Relationship between anticancer drug sensitivity and expression of p53,Bcl-2 proteins" X VIworld Congress of Otorhinolaryngology Head and Neck Surgey. 347-351 (1997)
T.OGAWA:“抗癌药物敏感性与 p53、Bcl-2 蛋白表达的关系”第六届世界耳鼻咽喉头颈外科大会。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Hideo FUKANO: "A STUDY OF ANTICANCER DRUG SENSITIVITY USING SDI TEST FOR HEAD AND NECK CARCINOMA" Head and Neck Cancer. 22. 482-487 (1996)
Hideo FUKANO:“使用头颈癌 SDI 测试进行抗癌药物敏感性研究” 头颈癌。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
T.OGAWA: "Relationship between anticancer drug sensitivity and expression of p53, Bcl-2 proteins" X VI world Congress of Otorhinolaryngology Head and Neck Surgery. 347-351 (1997)
T.OGAWA:“抗癌药物敏感性与 p53、Bcl-2 蛋白表达的关系”第六届世界耳鼻咽喉头颈外科大会。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

HASEGAWA Yasuhisa其他文献

HASEGAWA Yasuhisa的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('HASEGAWA Yasuhisa', 18)}}的其他基金

Wearable unloading device based on motion support technology
基于运动支撑技术的可穿戴卸载装置
  • 批准号:
    24650381
  • 财政年份:
    2012
  • 资助金额:
    $ 0.45万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Homeostatic enhancement technologies to increase affinity of wearable assistive gear
稳态增强技术可提高可穿戴辅助装备的亲和力
  • 批准号:
    21686025
  • 财政年份:
    2009
  • 资助金额:
    $ 0.45万
  • 项目类别:
    Grant-in-Aid for Young Scientists (A)
R&D of wearable powered hand with human finger properties
  • 批准号:
    19760162
  • 财政年份:
    2007
  • 资助金额:
    $ 0.45万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Molecular targets of 5FU and combined chemotherapy of 5FU plus low dose CDDP for head and neck cancer
5FU和5FU加低剂量CDDP联合化疗治疗头颈癌的分子靶点
  • 批准号:
    13671812
  • 财政年份:
    2001
  • 资助金额:
    $ 0.45万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Predictability of chemosensitivity of histoculture drug response assays and status of p53 gene for organ preservation therapy using neoadjuvant chemotherapy in patients with head and neck carcinomas
头颈癌患者新辅助化疗器官保存治疗中组织培养药物反应测定的化疗敏感性和 p53 基因状态的预测
  • 批准号:
    11671719
  • 财政年份:
    1999
  • 资助金额:
    $ 0.45万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A study of drug resistance and predilection of clinical response to chemotherapy (5FU/Cisplatin) in Head and Neck Cancer
头颈癌化疗(5FU/顺铂)的耐药性和临床反应倾向研究
  • 批准号:
    09671778
  • 财政年份:
    1997
  • 资助金额:
    $ 0.45万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)

相似海外基金

Development of a novel translymphatic chemotherapy using anti-EGFR antibody for metastatic lymph nodes of head and neck cancer
使用抗 EGFR 抗体开发用于头颈癌转移性淋巴结的新型经淋巴化疗
  • 批准号:
    16K11247
  • 财政年份:
    2016
  • 资助金额:
    $ 0.45万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A novel lymphatic chemotherapy targeting metastatic lymph nodes in patients with head and neck cancer using anti-cancer drugs combined with micelle
抗癌药物联合胶束针对头颈癌患者转移淋巴结的新型淋巴化疗
  • 批准号:
    25462693
  • 财政年份:
    2013
  • 资助金额:
    $ 0.45万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Sensitization for chemotherapy and radiation by gene induction which suppresses DNA repair in head and neck cancer
通过抑制头颈癌 DNA 修复的基因诱导对化疗和放疗增敏
  • 批准号:
    23592544
  • 财政年份:
    2011
  • 资助金额:
    $ 0.45万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of a novel approach to translymphatic chemotherapy targeting sentinel lymph nodes of patients with head and neck cancer
开发针对头颈癌患者前哨淋巴结的经淋巴化疗新方法
  • 批准号:
    22591920
  • 财政年份:
    2010
  • 资助金额:
    $ 0.45万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Is the improvement in survival for HPV associated head and neck cancer due to the addition of chemotherapy to radiotherapy or to a more treatment-sensitive cancer?
HPV 相关头颈癌生存率的改善是由于在放疗中添加化疗还是由于对治疗更敏感的癌症?
  • 批准号:
    211465
  • 财政年份:
    2010
  • 资助金额:
    $ 0.45万
  • 项目类别:
    Operating Grants
Is the improvement in survival for HPV associated head and neck cancer due to the addition of chemotherapy to radiotherapy or to a more treatment-sensitive cancer?
HPV 相关头颈癌生存率的改善是由于在放疗中添加化疗还是由于对治疗更敏感的癌症?
  • 批准号:
    199318
  • 财政年份:
    2009
  • 资助金额:
    $ 0.45万
  • 项目类别:
    Operating Grants
Customizing Adjuvant Chemotherapy in Head and Neck Cancer
头颈癌的定制辅助化疗
  • 批准号:
    19791222
  • 财政年份:
    2007
  • 资助金额:
    $ 0.45万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Development of a novel combined chemotherapy in head and neck cancer-combination of a DNA demethylating agent and an anticancer agent-
开发头颈癌新型联合化疗——DNA去甲基化剂和抗癌剂的组合——
  • 批准号:
    15390617
  • 财政年份:
    2003
  • 资助金额:
    $ 0.45万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Molecular targets of 5FU and combined chemotherapy of 5FU plus low dose CDDP for head and neck cancer
5FU和5FU加低剂量CDDP联合化疗治疗头颈癌的分子靶点
  • 批准号:
    13671812
  • 财政年份:
    2001
  • 资助金额:
    $ 0.45万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Basic study on chemotherapy combined with gene transfection for head and neck cancer
化疗联合基因转染治疗头颈癌的基础研究
  • 批准号:
    10470354
  • 财政年份:
    1998
  • 资助金额:
    $ 0.45万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B).
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了